Journals / Türk Klinik Biyokimya Dergisi / 2015 / Cilt: 13 - Sayı: 1

Comparison of Two Different Intact Parathyroid Hormone Assays in Patients with Chronic Kidney Disease

Kronik Böbrek Hastalarında İki Cihazın İntakt Paratiroid Hormon Ölçümünün Karşılaştırılması

Pages
21–28
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Clinicians should be informed about the bias between the methods and this bias should be taken into account in clinical decision point

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Intact parathyroid hormone is used for diagnostic follow up in chronic kidney disease mineral bone disorder.
📊
Key Findings & Data:Materials and Methods: We used blood sample of 41 patients with chronic kidney disease.
💡
Conclusion & Impact:Clinicians should be informed about the bias between the methods and this bias should be taken into account in clinical decision point
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Intact parathyroid hormone is used for diagnostic follow up in chronic kidney disease mineral bone disorder. Studies have shown that there was considerable bias between methods intact parathyroid hormone assays. This study has investigated the variation between intact parathyroid hormone assays using Access intact parathyroid hormone and Roche intact parathyroid hormone and if there is a bias, how this affect clinical decision level. Materials and Methods: We used blood sample of 41 patients with chronic kidney disease. Intact parathyroid hormone levels were measured with Access intact parathyroid hormone assay kit through UniCel DxI 800 autoanalyser (Beckman Coulter, Inc., Fullerton, U.S.A.) and Roche intact parathyroid hormone assay kit through Cobas e 601 autoanalyser (Roche Diagnostics GmbH, Mannheim, Germany). The results were divided into groups according to the decision points determined by the manuals. Results were statistically evaluated. Results: In Passing-Bablock analyse we found the following equation, y= -9.56 + 0.91 x (confident interval for intercept: -24.52 to 0.41, for slope: 0.87 to 0.950). There was no significant deviation from linearity (p>0.05). We found a 16.1 % difference between two methods in Bland–Atman plot analysis. The moderate agreement was found between clinical decision points determined by two methods using the Kappa test (κ = 0.437). Conclusion: We show that there is moderate agreement between Access intact parathyroid hormone assay and Roche intact parathyroid hormone assay results. We also show that there are differences between both methods. Clinicians should be informed about the bias between the methods and this bias should be taken into account in clinical decision point

Özet

Amaç: Kronik böbrek hastalığının mineral ve kemik bozukluğunun tanı amaçlı takibinde intakt paratiroid hormon düzeyi kullanılmaktadır. Yapılan çalışmalar intakt paratiroid hormon ölçüm yöntemleri arasında önemli oranda bias olduğunu göstermiştir. Biz bu çalışmamızda Access intakt paratiroid hormon ile Roche intakt paratiroid hormon arasında bias olup olmadığını, bias sözkonusu ise bunu klinik karar noktasındaki etkisini değerlendirmeyi amaçladık. Gereç ve Yöntem: Bu çalışma için hastanemiz diyaliz merkezinde diyalize girmekte olan 41 kronik böbrek hastasının kan örnekleri kullanılmıştır. İntakt paratiroid hormon ölçümleri; Access intakt paratiroid hormon ölçüm kiti aracılığı ile UniCel DxI 800 otoanalizöründe (Beckman Coulter, Inc., Fullerton, U.S.A.) ve Roche intakt paratiroid hormon ölçüm kiti aracılığı ile Cobas e601 otoanalizöründe gerçekleştirildi (Roche Diagnostics GmbH, Mannheim, Germany). Elde edilen sonuçlar kılavuzlar tarafından belirlenen karar noktalarına göre gruplara ayrıldı. Sonuçlar istatistiksel olarak değerlendirildi. Bulgular: Bland-Altman Plot ile bu yöntemlerin ortalamalarına karşı farkları incelendiğinde Roche intakt paratiroid hormon sonuçlarının Access intakt paratiroid hormon sonuçlarından %16,1 daha yüksek sonuç verdiği saptandı. Passing-Bablok Regresyon analizinde y= -9,56 + 0,91 x denklemi elde edildi. Güven aralığının kesişim için -24,52 ile 0,41 aralığında, eğim için 0,87 ile 0,95 aralığında olduğu ve lineariteden anlamlı bir sapma olmadığı görüldü (p>0,05). Kappa analizi ile klinik karar noktaları ile belirlenen tedavi grupları karşılaştırıldığında iki yöntemle elde edilen sonuçlar arasında orta derecede bir uyum olduğu sonucuna varıldı (? = 0.437). Sonuç: Access intakt paratiroid hormon sonuçları Roche intakt paratiroid hormon sonuçları ile uyumlu olmakla birlikte bazı farklılıklara da sahiptir. Yöntemler arası bias klinisyenlerle paylaşılmalı ve klinik karar noktasında bu bias göz önünde bulundurulmalıdır

🔖

Cite This Article

TEKÇE, H., TEKÇE, B. K. (2022). Comparison of Two Different Intact Parathyroid Hormone Assays in Patients with Chronic Kidney Disease. Türk Klinik Biyokimya Dergisi, Cilt: 13 - Sayı: 1, 21–28. https://ajindex.com/articles/634444

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Eknoyan G, Lameire N, Barsoum R, Eckardt KU, Levin A, Levin N, et al. The burden of kidney disease: improving global outcomes. Kidney Int 2004; 66:1310-4
  2. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int 2009: S1-130
  3. Estepa JC, Aguilera-Tejero E, Lopez I, Almaden Y, Rodriguez M, Felsenfeld AJ. Effect of phosphate on parathyroid hormone secretion in vivo. J Bone Miner Res 1999;14:1848-54
  4. Noordzij M, Korevaar JC, Boeschoten EW, Dekker FW, Bos WJ, Krediet RT, et al. The Kidney Disease Outcomes Quality Initiative (K/DOQI) Guideline for Bone Metabolism and Disease in CKD: association with mortality in dialysis patients. Am J Kidney Dis 2005;46:925-32
  5. Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006;69:1945-53
  6. Goldsmith DJ, Covic A, Fouque D, Locatelli F, Olgaard K, Rodriguez M, et al. Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guidelines: a European Renal Best Practice (ERBP) commentary statement. Nephrol Dial Transplant 2010;25:3823-31
  7. Steddon S, Sharples E. Renal Association Clinical Practice Guideline in mineral and bone disorders in CKD. Nephron Clin Pract 2011;118:c145-52
  8. Pontoriero G, Cozzolino M, Locatelli F, Brancaccio D. CKD patients: the dilemma of serum PTH levels. Nephron Clin Pract 2010;116:c263-8
  9. Murray TM, Rao LG, Divieti P, Bringhurst FR. Parathyroid hormone secretion and action: evidence for discrete receptors for the carboxyl-terminal region and related biological actions of carboxylterminal ligands. Endocr Rev 2005;26:78-113
  10. Brossard JH, Lepage R, Cardinal H, Roy L, Rousseau L, Dorais C, et al. Influence of glomerular filtration rate on non-(1-84) parathyroid hormone (PTH) detected by intact PTH assays. Clin Chem 2000; 46:697-703
  11. Souberbielle JC, Roth H, Fouque DP. Parathyroid hormone measurement in CKD. Kidney Int 2010; 77:93-100
  12. Lepage R, Roy L, Brossard JH, Rousseau L, Dorais C, Lazure C, et al. A non-(1-84) circulating parathyroid hormone (PTH) fragment interferes significantly with 3. Souberbielle JC, Cavalier E, Jean G. Interpretation of serum p